Skip to main content

Advertisement

Table 2 Proportion of all patients and patients with recurrence/metastasis and CD44/CD24 data with CD44+/CD24-/low tumor cells

From: CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

  n All cases (%) P n Recurrence/metastatic cases (%) P*
Age (years)
< 50 74 18.34 ± 2.70 0.444 34 24.91 ± 3.79 0.022
≥ 50 73 15.45 ± 2.66   38 13.20 ± 3.32  
Tumor size
T1 47 15.78 ± 2.86 0.224 15 13.19 ± 3.53  
T2 76 20.12 ± 2.90   44 23.78 ± 3.68  
T3 + T4 17 10.27 ± 4.46   13 11.83 ± 6.60 0.152
Lymph node involvement
Absent 32 8.66 ± 2.70 0.026 18 10.00 ± 3.77 0.075
Present 115 19.20 ± 2.29   54 21.53 ± 3.19  
TNM stage
I + II 70 15.87 ± 2.63 0.500 33 16.88 ± 3.74 0.368
III + IV 77 18.49 ± 2.81   39 21.73 ± 3.79  
ER expression
Negative 90 16.49 ± 2.47 0.845 47 18.92 ± 3.17 0.944
Positive 57 17.26 ± 3.07   25 19.32 ± 4.81  
PR expression
Negative 83 13.09 ± 2.41 0.038 43 14.63 ± 3.06 0.046
Positive 64 21.06 ± 2.98   29 25.32 ± 4.51  
Her2 expression
Negative 77 16.18 ± 3.03 0.566 38 17.36 ± 4.17 0.441
Positive 70 18.47 ± 2.61   34 21.57 ± 3.47  
Basal-like feature
Absent 108 18.44 ± 2.24 0.143 49 11.70 ± 4.07 0.050
Present 39 11.93 ± 3.66   23 22.66 ± 3.30  
Recurrence or metastasis
Absent 75 14.26 ± 2.72 0.246    
Present 72 18.73 ± 2.58     
Lesions in recurrence/metastatic patients
Primary     56 15.39 ± 2.63 0.014
Secondary     16 30.41 ± 6.46  
  1. * Calculated by t tests. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
  2. Immunohistochemically negative for both SR and Her2.